CARGLUMIC ACID
Clinical safety rating: caution
Comprehensive clinical and safety monograph for CARGLUMIC ACID (CARGLUMIC ACID).
Carglumic acid is a structural analog of N-acetylglutamate (NAG) and acts as a replacement for NAG in the urea cycle. It activates carbamoyl phosphate synthetase 1 (CPS1), the first enzyme of the urea cycle, by binding to the allosteric site that normally binds NAG, thereby promoting the conversion of ammonia to urea and reducing hyperammonemia.
| Metabolism | Carglumic acid is not significantly metabolized; it is primarily excreted unchanged in the urine. |
| Excretion | Primarily renal (approximately 80% as unchanged drug); minor biliary/fecal elimination (<5%) |
| Half-life | Terminal elimination half-life is approximately 4-6 hours in adults; prolonged in renal impairment |
| Protein binding | Approximately 97-99% bound to albumin |
| Volume of Distribution | 0.3-0.4 L/kg; confined primarily to extracellular fluid |
| Bioavailability | Oral: approximately 30-40% (due to extensive first-pass metabolism) |
| Onset of Action | Oral: clinical effect on ammonia reduction observed within 2-4 hours; intravenous: not applicable |
| Duration of Action | Duration of ammonia-lowering effect is approximately 4-6 hours; requires multiple daily dosing |
100-250 mg/kg/day orally, divided into 3-4 doses, maximum 250 mg/kg/day.
| Dosage form | TABLET, FOR SUSPENSION |
| Renal impairment | No specific dose adjustment recommended; use with caution in severe renal impairment (eGFR <30 mL/min/1.73 m²). |
| Liver impairment | No dose adjustment required for hepatic impairment. |
| Pediatric use | 100-250 mg/kg/day orally, divided into 3-4 doses; maximum 250 mg/kg/day. Safety and efficacy not established in neonates <3 months. |
| Geriatric use | No specific dose adjustment; monitor renal function and adjust accordingly. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for CARGLUMIC ACID (CARGLUMIC ACID).
| Breastfeeding | No human data; M/P ratio unknown. Excretion into human milk is unknown; caution recommended. |
| Teratogenic Risk | Inadequate human data; animal studies not available. Use only if maternal benefit outweighs potential fetal risk. No known teratogenicity reported. |
| Fetal Monitoring | Monitor serum ammonia, liver function, and clinical signs of hyperammonemia. Fetal ultrasound for growth and development if used during pregnancy. |
■ FDA Black Box Warning
None.
| Serious Effects |
["Hypersensitivity to carglumic acid or any component of the formulation"]
| Precautions | ["Risk of hypersensitivity reactions including bronchospasm and rash","Monitor ammonia levels closely during therapy","Use with caution in patients with renal impairment due to potential accumulation","May cause dizziness or somnolence; caution when driving or operating machinery"] |
| Food/Dietary | Administer capsules immediately before meals or mixed with food to enhance absorption. Avoid high-protein meals in NAGS deficiency patients to reduce ammonia production. No specific food-drug interactions reported; but maintain consistent dietary protein intake as per metabolic management plan. |
Loading safety data…
| Fertility Effects | No specific effects on fertility reported in humans; animal studies not conducted. |
| Clinical Pearls | Carglumic acid is a structural analog of N-acetylglutamate (NAG) and activates carbamoyl phosphate synthetase I (CPS I) in the urea cycle. It is used for acute and maintenance therapy of hyperammonemia due to N-acetylglutamate synthase (NAGS) deficiency. Monitor ammonia levels closely; goal is normalization within 24-48 hours. Carglumic acid is rapidly absorbed; take immediately before meals. Doses >100 mg/kg/day may cause GI distress. Avoid concomitant use with valproic acid unless necessary, as valproate may exacerbate hyperammonemia. |
| Patient Advice | Take carglumic acid immediately before meals or mixed with a small amount of formula/food to improve absorption. · Do not crush or chew tablets; dissolve tablets in water or juice immediately before administration. · Monitor for signs of high ammonia (vomiting, lethargy, irritability, confusion) and seek emergency care if occur. · Store tablets in original container at room temperature; do not remove desiccant. · Women of childbearing age should use effective contraception; pregnancy requires careful management. · Report any persistent nausea, vomiting, or diarrhea to your healthcare provider. |